Filing Flows › CareDx (CDNA) › Q3 2026 › vs Q2 2026
CareDx (CDNA) Q3 2026 vs Q2 2026 (quarter over quarter)
CareDx's revenue rose $7.4M (+6%) from $132M in Q2 2026 to $139M in Q3 2026. The biggest changes: Testing services revenue +$19.3M (+19%); Patient and digital solutions revenue +$941K (+5%). Operating margin 5.8% against 85.8% (-80.0 pts).
CareDx, Q3 2026: revenue $139M (+39% year over year), operating margin 5.8%, net earnings $19.3M, operating cash flow $12.7M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 5.8% | 85.8% | -80.0 pts |
| Net margin | 13.8% | 83.8% | -70.0 pts |
| Free cash flow margin | 8.0% | 21.8% | -13.8 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Testing services revenue | $119M | $99.9M | $19.3M | +19% |
| Patient and digital solutions revenue | $20.2M | $19.2M | $941K | +5% |
| Revenue | $139M | $132M | $7.4M | +6% |
| Other income, net | $2.6M | $1.3M | $1.3M | +99% |
| Operating profit | $8.1M | $113M | −$105M | -93% |
| Costs & expenses | $131M | $18.7M | $113M | +601% |
| Pre-tax earnings | $10.7M | $115M | −$104M | -91% |
| Income tax benefit | $8.6M | −$3.9M | $12.5M | — |
| Net earnings | $19.3M | $111M | −$91.3M | -83% |
| Operating cash sources | $36.2M | $124M | −$88.0M | -71% |
| Depreciation & amortization | $7.2M | $2.8M | $4.4M | +156% |
| Share-based compensation | $9.7M | $10.7M | −$999K | -9% |
| Working capital & other | $23.4M | $93.5M | −$70.1M | -75% |
| Operating cash flow | $12.7M | $30.6M | −$17.9M | -58% |
| Free cash flow (OCF − capex) | $11.1M | $28.7M | −$17.6M | -61% |
| Capital expenditures | $1.6M | $1.9M | −$243K | -13% |
Questions
How much did CareDx's revenue grow quarter over quarter in Q3 2026?
CareDx's revenue rose $7.4M (+6%) from $132M in Q2 2026 to $139M in Q3 2026.
What drove CareDx's revenue change in Q3 2026?
Testing services revenue +$19.3M (+19%); Patient and digital solutions revenue +$941K (+5%).